Abstract-Patients with chronic renal failure often have hypertension, but the cause of hypertension, other than an excess of body fluid, is not well known. We hypothesized that the bulbospinal neurons in the rostral ventrolateral medulla (RVLM) are stimulated by uremic toxins in patients with chronic renal failure. To investigate whether RVLM neurons are sensitive to uremic toxins, such as uric acid, indoxyl sulfate, or methylguanidine, we examined changes in the membrane potentials (MPs) of bulbospinal RVLM neurons of Wister rats using the whole-cell patch-clamp technique during superfusion with these toxins. A brainstem-spinal cord preparation that preserved the sympathetic nervous system was used for the experiments. During uric acid, indoxyl sulfate, or methylguanidine superfusion, almost all the RVLM neurons were depolarized. To examine the transporters for these toxins on RVLM neurons, histological examinations were performed. The uric acid-, indoxyl sulfate-, and methylguanidine-depolarized RVLM neurons showed the presence of urate transporter 1 (URAT 1), organic anion transporter (OAT)1 or OAT3, and organic cation transporter (OCT)3, respectively. Furthermore, the toxin-induced activities of the RVLM neurons were suppressed by the addition of an anti-oxidation drug (VAS2870, an NAD(P)H oxidase inhibitor), and a histological examination revealed the presence of NAD(P)H oxidase (nox)2 and nox4 in these RVLM neurons. The present results show that uric acid, indoxyl sulfate, and methylguanidine directly stimulate bulbospinal RVLM neurons via specific transporters on these neurons and by producing oxidative stress. These uremic toxins may cause hypertension by activating RVLM neurons. 
INTRODUCTION
The mechanisms responsible for hypertension during chronic renal failure are not well known. The major determinants of the blood pressure (BP) are the cardiac output, blood volume, fluid viscosity, overall vascular compliance, and peripheral vascular resistance (Mayet and Hughes, 2003) . In patients with chronic renal failure, while an increase of the body fluid volume is considered to be one of the major causes of hypertension (Vasavada and Agarwal, 2003) , there are many renal failure patients with hypertension who do not necessarily show an excess of body fluid (Odudu and McIntyre, 2012) . Wabel et al. (2008) showed that volume-dependent hypertension was observed in only 15% of patients with chronic renal failure. The removal of uremic toxins through dialysis often improves hypertension (Vasavada and Agarwal, 2003) , but the mechanism by which uremic toxins cause hypertension is obscure. The rostral ventrolateral medulla (RVLM), which contains presympathetic neurons, is known to be a pivotal region that regulates BP (Madden and Sved, 2003) . The neurons in the RVLM project to the intermediolateral cell column (IML), where they connect with the sympathetic preganglionic neurons that regulate the peripheral sympathetic function and BP (Dembowsky et al., 1986; Pilowsky and Goodchild, 2002) . Therefore, if uremic toxins activated these neurons, the BP would increase. Thus, in this study, we examined the direct effects of uremic toxins (uric acid, indoxyl sulfate, and methylguanidine) on bulbospinal RVLM neurons.
Some previous reports have discussed the effects of hyperuricemia on hypertension (Sa´nchez-Lozada et al., 2008; Nagahama et al., 2015) . Hyperuricemia reportedly up-regulates the renin-angiotensin-system (Corry et al., 2008) , but the mechanism is not well known. Regarding indoxyl sulfate, Liu et al. (2012) showed that the accumulation of indoxyl sulfate affects hypertension, and al. (2012a) showed that indoxyl sulfate significantly activates the renal renin-angiotensin-system. Methylguanidine also is reported to give effects on BP. Sorrentino and Pinto (1995) showed that intravenous administration of methylguanidine increased the mean BP in a dose-dependent manner in rats and suggested that the rise in the plasma concentration of methylguanidine may contribute to the hypertension seen in patients with chronic renal failure.
To the best of our knowledge, the direct effects of uremic toxins on bulbospinal RVLM neurons have not been previously reported. Previous studies have demonstrated that these uremic toxins enter the target cells through specific transporters (Enomoto et al., 2003; Taki et al., 2006; Endou and Anzai, 2008; Tachikawa and Hosoya, 2011) and damage the cells by producing oxidative stress (Ksiazek and Załuska, 2008; Tumur and Niwa, 2009; Wang et al., 2010; Shimizu et al., 2013) . Therefore, in this study, we examined the effects of uric acid, indoxyl sulfate and methylguanidine on the bulbospinal RVLM neurons using brainstemspinal cord preparations (Oshima et al., 2008 (Oshima et al., , 2013 (Oshima et al., , 2014 ; we also conducted histological analysis to check for the presence of specific transporters for these uremic toxins on the RVLM neurons. To confirm the effects of oxidative stress produced by these toxins, we investigated the effects of VAS2870 (an NAD(P)H oxidase inhibitor) on the RVLM neurons and conducted histological evaluation to check for the presence of NAD(P)H oxidase (nox) in the RVLM neurons.
EXPERIMENTAL PROCEDURES

General preparations
Experiments were performed using brainstem-spinal cord preparations collected from 1-to 5-day-old Wistar rats, as previously described (Oshima et al., 2008 (Oshima et al., , 2013 (Oshima et al., , 2014 . The experiment protocols were approved by the Institutional Review Board of National Defense Medical College and were in accordance with the National Guidelines for the Conduct of Animal Experiments. Briefly, the animals were placed under deep ether anesthesia and the brainstem-spinal cord was isolated at the Th 2 level; the brainstem was then sectioned between the roots of cranial nerve VI and the lower border of the trapezoid body (Fig. 1a) . The preparations were continuously superfused with a solution containing (in mmol/L) 124 NaCl, 5.0 KCl, 1.2 KH 2 PO 4 , 2.4 CaCl 2 , 1.3 MgCl 2 , 26 NaHCO 3 , and 30-glucose and maintained at 25-26°C (artificial cerebrospinal fluid [aCSF] ). The pH (7.4) and oxygenation were maintained by bubbling 90% O 2 -5% N 2 -5% CO 2 through the solution.
Patch-clamp electrodes
Electrodes were pulled in one stage from thin-wall borosilicate filament capillaries (GC100TF-10, outer diameter 1.0 mm; Clark Electromed, Reading, UK) with a vertical puller. The electrodes had a tip diameter of 1.8-2.0 lm and a resistance of 4-6 MX. The electrode solution for the whole-cell recordings consisted of (in mmol/L): 130 potassium gluconate, 10 HEPES, 10 EGTA, 1 CaCl 2, and1 MgCl 2 , with the pH adjusted to 7.2-7.3 with KOH. The electrode tips were filled with 0.2% Lucifer Yellow (Sigma, St. Louis, MO, USA).
Recording procedure
A patch-clamp amplifier (AxoPatch, ID; Axon Instruments, Sunnyvale, CA, USA) was used to record the membrane potentials (MPs). The RVLM neurons were sought from the ventral side of the medulla. To confirm that the recorded RVLM neuron was a bulbospinal neuron, the existence of antidromic action potentials (APs) in the RVLM neurons was examined by electrical stimulation of the IML at the Th 2 level with a tungsten electrode (30-lm tip diameter; Unique Medical, Tokyo, Japan) (Fig. 1b) . The MPs were recorded using the currentclamp technique (20 pA increments from À100 to 20 pA, 500 ms in duration). All data were recorded and analyzed using PowerLab (AD Instruments, Colorado Springs, CO, USA). The membrane resistances (MRs) of the RVLM neurons were calculated from the currentvoltage curves. During the course of the whole-cell recordings, neurons were labeled with 0.2% Lucifer Yellow (lithium salt; Sigma) by either spontaneous diffusion or iontophoresis. drug. The bulbospinal RVLM neurons were superfused with tetrodotoxin (TTX, 0.5 mmol/L [Oshima et al., 2014] , Sigma) solution for 10 min to block synaptic transmissions from other neurons to the recorded bulbospinal RVLM neurons. Thereafter, the neurons were superfused with each toxin (uric acid, 0.5 mmol/L; indoxyl sulfate, 1 mmol/L; and methylguanidine, 1 mmol/L) dissolved in a TTX solution and the MPs were recorded.
Experimental protocols
Protocol (2). To examine whether the changes in RVLM neuron activities caused by uric acid, indoxyl sulfate, or methylguanidine superfusion were transmitted to the IML neurons, the MPs of the IML neurons were recorded and the RVLM areas were micro-superfused (10-30 lL) with each toxin solution (uric acid, 0.5 mmol/L; indoxyl sulfate, 0.5 mmol/L; or methylguanidine, 0.5 mmol/L) (Fig. 6a) . The brain surface over the RVLM was superfused with each of the toxins.
Protocol (3).
To examine whether the effects of these uremic toxins on RVLM neurons were caused by an increase in oxidative stress, VAS2870 (40-80 lmol/L [Sun et al., 2012b] , Sigma) was added to each toxin solution (uric acid, 0.5 mmol/L; indoxyl sulfate, 0.5 mmol/L; or methylguanidine, 0.5 mmol/L) during the recording of the MPs of the bulbospinal RVLM neurons.
Immunofluorescence staining
To determine the presence of specific transporters for these toxins histologically, immunofluorescence staining was performed. After the aforementioned experiments, the preparations were fixed for 1 h at 4°C in 4% paraformaldehyde in 0.1 m PBS, immersed in 18% sucrose-PBS overnight, embedded in optimal cutting temperature compound (Sakura Finetek, Tokyo, Japan), frozen on dry ice, and cut into 20-lm-thick transverse sections, followed by immunofluorescence staining. The images were obtained using a conventional fluorescence microscope (LSM510; Carl Zeiss Co., Oberkochen, Germany).
Immunofluorescence staining protocols
The Lucifer Yellow-stained RVLM neurons that responded to uric acid, indoxyl sulfate, or methylguanidine were examined for each toxin's specific transporter. The following primary antibodies (1:400 dilution) were used for immunofluorescence: rabbit anti-URAT1 (SLC22A12) antibody (Santa Cruz Biotechnology, Dallas, TX, USA), rabbit anti-organic anion transporter (OAT)1 (SLC22A6) antibody (Sigma), rabbit anti-OAT3 (SLC22A8) antibody (Sigma), and rabbit anti-organic cation transporter (OCT)3 (SLC22A3) antibody (Sigma). To confirm that the examined area was a C1 area, the existence of tyrosine hydroxylase (TH)-positive neurons in the RVLM was also examined using mouse anti-TH antibody (Sigma). The secondary antibodies for fluorescence staining (1:1000 dilution) were Alexa Fluor 546 goat anti-rabbit immunoglobulin G (IgG) (Molecular Probes/Invitrogen, Eugene, OR, USA) and Alexa Fluor 633 goat anti-mouse IgG (Molecular Probes/Invitrogen).
To determine whether depolarization of the RVLM neurons induced by these uremic toxins was induced by an increase in oxidative stress via nox, the expression of nox1, nox2, or nox4 was examined in RVLM neurons after the preparations were superfused with these toxins. The following primary antibodies were used for immunofluorescence: goat anti-nox1 antibody (Sigma), rabbit anti-nox2 antibody (Abcam, Cambridge, CB, UK), goat anti-nox2 antibody (Abcam), and rabbit anti-nox4 (Santa Cruz Biotechnology, Dallas, TX, USA). The secondary antibodies used for the immunofluorescence staining were Alexa Fluor 633 donkey anti-goat IgG and Alexa Fluor 546 donkey anti-rabbit IgG.
Statistics
The results were expressed as mean ± SEM. Comparisons of the MPs recorded before and during (or after) superfusion with the drugs were performed using the Student's t-test for paired observations. Statistical significance was set at P < 0.05.
RESULTS
Effects of uremic toxins on bulbospinal RVLM neurons
To examine the effects of uremic toxins on the bulbospinal RVLM neurons, we superfused the bulbospinal RVLM neurons with each uremic toxin.
Uric acid superfusion: Of the 33 recorded bulbospinal RVLM neurons, 29 showed depolarization and an increased frequency of action potential (FAP) during uric acid superfusion (0.05-1 mmol/L) (Fig. 2a, a1 , a2, b, Table 1 ).
Superfusion of uric acid dissolved in TTX solution. All the four recorded bulbospinal RVLM neurons showed depolarization during superfusion of uric acid dissolved in TTX solution (MP: before: À42.2 ± 0.4 mV; during: À38.4 ± 0.7 mV; P < 0.05) (Fig. 2c) .
Indoxyl sulfate superfusion. All the 14 recorded bulbospinal RVLM neurons showed depolarization during indoxyl sulfate superfusion (0.01-5 mmol/L) ( Fig. 3a, a1 , a2, b, Table 2 ).
Superfusion of indoxyl sulfate in TTX solution. All the four recorded bulbospinal RVLM neurons showed depolarization during superfusion of indoxyl sulfate dissolved in TTX solution (before: À47.4 ± 1.5 mV; during: À44.8 ± 1.6 mV; P < 0.05) (Fig. 3c) .
Methylguanidine superfusion. Of the 29 recorded RVLM neurons, 27 showed depolarization during methylguanidine superfusion (0.001-5 mmol/L) (Fig. 4a,  a1 , a2, b, Table 3 ).
Superfusion of methylguanidine in TTX solution. All the five recorded bulbospinal RVLM neurons recorded showed depolarization during superfusion of methylguanidine dissolved in TTX solution (before, À44.3 ± 0.7 mV; during, À40.9 ± 0.7 mV; P < 0.01) (Fig. 4c) .
The MRs tended to decrease during exposure to each uremic toxin. Overall, however, we observed no statistically significant changes in the MRs during superfusion of the neurons with each of the toxins.
Effects of VAS2870 on uremic toxin-depolarized RVLM neurons
During VAS2870 (40-80 lmol/L) superfusion, eight of the 10 bulbospinal RVLM neurons were hyperpolarized (before, À42.6 ± 1.0 mV; during, À45.8 ± 1.0 mV; P < 0.01; FAP: before, 0.8 ± 0.1 Hz; during, 0.1 ± 0.1 Hz; P < 0.05).
To examine the effects of VAS2780 on uremic toxindepolarized RVLM neurons, we added VAS2870 to a solution in which one of the toxins had been dissolved. In all of the five cases, the addition of VAS2870 hyperpolarized the uric acid-depolarized RVLM neurons (before: À41.2 ± 2.9 mV; during: À46.2 ± 3.2 mV; P < 0.05; before: 1.7 ± 0.8 Hz; during: 0.2 ± 0.1 Hz) (Fig. 5a, a1, a2 ). The addition of VAS2870 hyperpolarized the uric acid-depolarized neurons in a concentration-dependent manner. In nine of the 10 neurons, the addition of VAS2870 hyperpolarized the indoxyl sulfate-depolarized RVLM neurons (before, À40.2 ± 0.7 mV; during, À44.3 ± 0.4 mV; P < 0.01; before, 0.7 ± 0.2 Hz; during, 0.2 ± 0.1 Hz) (Fig. 5b, b1,  b2 ). In all of the five neurons, the addition of VAS2870 hyperpolarized the methylguanidine-depolarized RVLM neurons (before, À39.8 ± 1.0 mV; during, À44.4 ± 1.7 mV; P < 0.05; before, 1.2 ± 0.3 Hz; during, 0.1 ± 0.2 Hz; P < 0.05) (Fig. 5c, c1, c2 ).
Micro-superfusion with a uremic toxin solution over an RVLM area
To examine whether the changes in the activities of the RVLM neurons by the uremic toxins were transmitted to the IML neurons, we micro-superfused the RVLM areas with each toxin solution and observed the changes of MPs of the IML neurons. In all of the four cases, microsuperfusion of the brain surface over the RVLM with a uric acid solution caused depolarization of the IML neurons at the Th 2 level (Fig. 6b, b1 , b2) (before: À45.9 ± 0.8 mV; after: À43.0 ± 1.3 mV; P < 0.05; before: 0.1 ± 0.1 Hz; after: 0.6 ± 0.1 Hz; P < 0.05). In all of the three cases, micro-superfusion of the brain surface over the RVLM with indoxyl sulfate solution activated the IML neurons at the Th 2 level (Fig. 6c, c1 , c2) (before: À41.1 ± 0.4 mV; after: À36.2 ± 0.5 mV; P < 0.01; before: 0.1 ± 0.1 Hz; after: 0.4 ± 0.1 Hz; P < 0.05). In all of the five cases, micro-superfusion of the brain surface over the RVLM with methylguanidine solution depolarized the IML neurons at the Th 2 level (Fig. 6d, d1 , d2) (before: À48.2 ± 1.8 mV; after: À44.2 ± 1.7 mV; P < 0.01; before: 0.4 ± 0.3 Hz; after: 1.6 ± 0.5 Hz; P < 0.05).
Immunoreactivity
To determine the presence of specific transporters for the uremic toxins histologically, we performed immunofluorescence staining. Lucifer Yellow staining was performed after the whole-cell recordings of the bulbospinal RVLM neurons were completed ( Fig. 7a-d) .
Five RVLM neurons that showed depolarization during uric acid superfusion were examined for URAT1 immunoreactivity, and we confirmed all of them were confirmed to be located in the RVLM and to show URAT1 immunoreactivity (Fig. 7a) . Two of these five neurons also showed immunoreactivity for TH (Fig. 7a) . Eight RVLM neurons that showed depolarization during indoxyl sulfate superfusion were examined for OAT1 (n = 4) or OAT3 (n = 4) immunoreactivity. As a result, all of the four indoxyl sulfate-depolarized neurons recorded showed immunoreactivity for OAT1, and all of the four indoxyl sulfate-depolarized neurons recorded showed immunoreactivity for OAT3 (Fig. 7b, c) . Two of the four OAT1-immunoactive and three of the four OAT3-immunoactive neurons also showed TH immunoreactivity (Fig. 7b, c) .
Five RVLM neurons that showed depolarization during methylguanidine superfusion were examined for OCT3 immunoreactivity, and all five neurons showed immunoreactivity for OCT3 (Fig. 7d) . Three of these five neurons also showed TH immunoreactivity (Fig. 7d) .
To determine the presence of nox histologically, we examined the immunoreactivity for nox1, nox2 and nox4, and several neurons in the RVLM were found to exhibit nox2 or nox4 immunoreactivity (examined in three rats) (Fig. 8a2, a3 ). In the RVLM area, most nox2-immunoreactive neurons also showed nox4 immunoreactivity (examined in four rats) (Fig. 8b1-3) . However, nox1-immunoreactive neurons were not observed (examined in three rats) (Fig. 8a1) .
Next, the uric acid-depolarized RVLM neurons that were hyperpolarized by the addition of VAS2870 were examined for nox4 immunoreactivity (n = 8), and all of them exhibited nox4 immunoreactivity. A representative image of a nox4-positive neuron is shown in Fig. 9a . The indoxyl sulfate-depolarized RVLM neurons that were hyperpolarized by the addition of VAS2870 were also examined for nox4 immunoreactivity (n = 4), and all of them exhibited nox4 immunoreactivity (Fig. 9b) . The methylguanidine-depolarized RVLM neurons that were hyperpolarized by the addition of VAS2870 were examined for nox4 immunoreactivity (n = 4), and all of them exhibited nox4 immunoreactivity (Fig. 9c) .
DISCUSSION
In this study, we examined whether uremic toxins (uric acid, indoxyl sulfate, and methylguanidine) depolarize bulbospinal RVLM neurons. The results showed that each toxin was capable of depolarizing the bulbospinal RVLM neurons (Figs. 2-4) . Furthermore, since the RVLM neurons showed depolarization during superfusion with each toxin dissolved in a TTX solution (Figs. 2c, 3c and 4c), each toxin was thought to affect the bulbospinal RVLM neurons themselves. To confirm whether the increased activities of the RVLM neurons affected the IML neurons, micro-superfusion with these toxins was performed on an RVLM area during wholecell recordings of an IML neuron at the Th 2 level. As a result, the IML neurons were found to be activated 2-5 s after the micro-superfusion of these toxins over the RVLM area (Fig. 6b-d) . IML neurons, which are projected by bulbospinal RVLM neurons, form the final common pathway of the central nervous system that regulates peripheral sympathetic function and BP (Cabot, 1990; Oshima et al., 2008) . Consequently, activated IML neurons increase peripheral sympathetic nerve activity. These results suggest that the administration of these toxins to RVLM neurons increases the peripheral sympathetic nerve activity and raises the BP.
Immunofluorescence staining showed the specific transporters for each of the toxins on the neurons (Fig. 7a-d) . The results suggested that each uremic toxin increased the activities of the bulbospinal RVLM neurons through its specific transporters.
RVLM neurons also include C1-catecholaminergic neurons (Madden and Sved, 2003; Oshima et al., 2014) . Therefore, we examined the TH immunoreactivity of each toxin-depolarized RVLM neuron and found that some of these neurons showed TH immunoreactivity ( Fig. 7a-d) , suggesting that catecholaminergic RVLM neurons have specific transporters for each toxin.
The mechanism of how uremic toxins activate RVLM neurons is not well known. However, some studies have shown that oxidative stress induces cell membrane depolarization (Koliwad et al., 1996) . Sa´nchez-Lozada et al. (2008) showed that indoxyl sulfate or uric acid induces oxidative stress in renal proximal tubular and vascular endothelial cells via nox4. Therefore, we examined the existence of nox in RVLM neurons. VAS2870 is a validated nox inhibitor (Altenho¨fer et al., 2012) and was added to each uremic toxin solution to examine whether VAS2870 diminishes the activities of RVLM neurons induced by each uremic toxin. As the results showed, VAS2870 suppressed the activities of these neurons, suggesting the presence of toxin-induced oxidative stress. The addition of VAS2870 hyperpolarized the uric acid-depolarized RVLM neurons in a concentration-dependent manner. During VAS2870 superfusion, the uric acid-depolarized RVLM neurons (n = 5) were hyperpolarized (a1), however, no significant changes of the FAP in the RVLM neurons were observed (a2). Black bar, before VAS2870 superfusion; gray bar, during VAS2870 superfusion; values are mean ± SEM. # P < 0.01 vs. before VAS2870 superfusion. (b) The addition of VAS2870 hyperpolarized the indoxyl sulfate-depolarized RVLM neuron. During VAS2870 superfusion, the indoxyl sulfate-depolarized RVLM neurons (n = 10) were hyperpolarized (b1), however, no significant changes of the FAP in the RVLM neurons were observed (b2). Black bar, before VAS2870 superfusion; gray bar, during VAS2870 superfusion; values are mean ± SEM. # P < 0.01 vs. before VAS2870 superfusion. (c) The addition of VAS2870 hyperpolarized the methylguanidine-depolarized RVLM neuron. During VAS2870 superfusion, the methylguanidine-depolarized RVLM neurons (n = 5) were hyperpolarized (c1), and the FAP in the RVLM neurons decreased (c2). Black bar, before VAS2870 superfusion; gray bar, during VAS2870 superfusion; values are mean ± SEM. * P < 0.05 vs. before VAS2870 superfusion.
Among the seven nox family members, nox1, nox2, and nox4 influence the cardiovascular system (Datla and Griendling, 2010) . Therefore, we examined the presence of nox1, nox2, and nox4 in RVLM neurons using immunofluorescence staining and were able to show the existence of nox2 and nox4 in RVLM neurons (Fig. 8a2,  a3, b) . In the RVLM area, the presence of nox2 has been reported by Rubattu et al. (2013) , but the presence of nox4 was not mentioned. In the present study, the presence of both nox2 and nox4 in the bulbospinal RVLM The IML neuron at the Th 2 level was depolarized after uric acid micro-superfusion over the RVLM area. After micro-superperfusion of the brain surface over the RVLM area with uric acid, the IML neurons (n = 4) were depolarized (b1), and the FAP in the IML neurons increased (b2). White bar, before uric acid superfusion; black bar, after uric acid superfusion; values are mean ± SEM. * P < 0.05 vs. before uric acid superfusion. (c) The IML neuron at the Th 2 level was depolarized after indoxyl sulfate micro-superfusion over the RVLM area. After micro-superfusion of the brain surface over the RVLM area with indoxyl sulfate, the IML neurons (n = 3) were depolarized (c1), and the FAP in the IML neurons increased (c2). White bar, before indoxyl sulfate superfusion; black bar, after indoxyl sulfate superfusion; values are mean ± SEM. * P < 0.05, # P < 0.01 vs. before indoxyl sulfate superfusion. (d) The IML neuron at the Th 2 level was depolarized after methylguanidine micro-superfusion over the RVLM area. After microsuperfusion of the brain surface over the RVLM area with methylguanidine, the IML neurons (n = 5) were depolarized (d1), and the FAP in the IML neurons increased (d2). White bar, before methylguanidine superfusion; black bar, after methylguanidine superfusion; values are mean ± SEM. neurons was demonstrated, and most of the nox4-stained neurons also demonstrated immunoreactivity for nox2 (Fig. 8b) . Furthermore, since uric acid, indoxyl sulfate, or methylguanidine-depolarized RVLM neurons showed nox4 expression, each toxin may stimulate RVLM neurons by increasing oxidative stress via nox2 and/or nox4 (Fig. 8a2, a3, b, 9a-c) .
Effects of uric acid on bulbospinal RVLM neurons
In the renal proximal tubular cells, uric acid enters the cells via URAT1 (Endou and Anzai, 2008) . In the present study, all the examined bulbospinal RVLM neurons, which were depolarized during uric acid superfusion, showed immunoreactivity for URAT1 (Fig. 7a) . These results suggest that uric acid increases BP by activating RVLM neurons through URAT1 on RVLM neurons. Bowman et al. (2010) showed that the level of uric acid in CSF is approximately one-tenth of the level of uric acid in plasma. A level of 0.05 mmol/L of uric acid (Fig. 2a,  a1 , a2, Table 1 ) in CSF corresponds to a level of 0.5 mmol/L (8.4 mg/dl) of uric acid in plasma, and such levels can be present in patients with hyperuricemia.
Effects of indoxyl sulfate on bulbospinal RVLM neurons
Since the specific transporters for IS are OAT1 and OAT3 (Enomoto et al., 2003; Taki et al., 2006) , we examined the presence of these transporters on RVLM neurons. In the present study, all the indoxyl sulfate-depolarized RVLM neurons showed immunoreactivity for OAT1 or OAT3 (Fig. 7b, c) . These results suggest that indoxyl sulfate activates bulbospinal RVLM neurons through OAT1 and/or OAT3 expressed on these neurons.
The blood concentration level of indoxyl sulfate in patients under hemodialysis therapy is 0.2-0.9 mmol/L (Mozar et al., 2012) . Although the level of indoxyl sulfate in CSF is not well known, Mu¨ting (1965) showed that the level of indoxyl sulfate in CSF under normal conditions is 3.4 times lower than that in plasma. Furthermore, Ohtsuki et al. (2002) suggested that the inhibition of brain-to-blood transport for indoxyl sulfate would occur in uremia, leading to the accumulation of indoxyl sulfate in the brain. Therefore, we considered that a level of 0.01 mmol/L of indoxyl sulfate (Fig. 3a, a1 , a2, Table 2) in CSF might be feasible in patients with uremia. Tachikawa and Hosoya (2011) showed that methylguanidine is a substrate for OCT3, and Gasser et al. (2009) indicated the existence of OCT3 in the brain. In this study, all methylguanidine-depolarized RVLM neurons exhibited immunoreactivity for OCT3 (Fig. 7d) . Methylguanidine was thought to increase the activities of RVLM neurons through OCT3 on these neurons.
Effects of methylguanidine on bulbospinal RVLM neurons
Methylguanidine is produced from creatinine by reacting with a hydroxyradical (Yokozawa et al., 1997) , and methylguanidine increased oxidative stress by producing H 2 O 2 (Marzocco et al., 2010) . However, the relation between methylguanidine and nox is unknown. In this study, VAS2870 solution decreased the MPs of methylguanidine-depolarized RVLM neurons to the level of the resting MPs of those neurons (Fig. 5c, c1) , and methylguanidine-depolarized neurons exhibited nox4 (Fig. 9c) . These results suggest that depolarization in RVLM neurons during methylguanidine superfusion is caused by oxidative stress produced via nox2 and/or nox4 (Fig. 8b) . Eloot et al. (2005) indicated that the plasma methylguanidine concentration in patients with chronic renal failure was 0.02-0.04 mmol/L. The methylguanidine concentration in the CSF of patients with uremia is not well known; however, De Deyn et al. (2001) reported that the highest methylguanidine concentration in CSF from their uremic patients was 0.001 mmol/L. In the present study, since the depolarizing effects of methylguanidine on RVLM neurons were observed even at a level of 0.001 mmol/L (Fig. 4a, a1, a2, Table 3 ), we thought that methylguanidine might participate in increasing the BP by stimulating RVLM neurons in patients with chronic renal failure.
Other possible causes of increase in the activities of the RVLM neurons Rossi et al. (2014) showed that the serum levels of uremic toxins were independently associated with the serum levels of interleukin-6 (IL-6), tumor necrosis factor-a (TNF-a) and interferon gamma (IFN-c) in patients with chronic kidney disease. Wu et al. (2012) showed that the cytokines IL-1b, IL-6, and TNF-a, accompanied by lipopolysaccharide-induced systemic inflammation, activate the microglia in the RVLM to induce neuroinflammation, which leads to an increase in the level of oxidative stress, which in turn, mediates neurogenic hypertension. Therefore, in patients with chronic renal failure, uremic toxins may cause hypertension by activating the RVLM neurons via induction of cytokines. However, in this study, we used the brainstem-spinal cord preparations of newborn rats in which systemic inflammation cannot be examined, but we observed depolarization of the bulbospinal RVLM neurons immediately after superfusion of each of the toxins. Therefore, we believe that uremic toxins can have direct effects on the RVLM neurons through their specific transporters.
CONCLUSIONS
Uremic toxins (uric acid, indoxyl sulfate, and methylguanidine) increased the activities of bulbospinal RVLM neurons, and the presence of transporters of URAT1, OAT1, or OAT3, and OCT3 in the bulbospinal RVLM neurons was demonstrated histologically. The toxin-induced activities of RVLM neurons were abolished by VAS2870 (a nox inhibitor), and the presence of nox2 and nox4 was confirmed histologically. Based on these results, uremic toxins may increase the sympathetic nervous activity in patients with chronic renal failure, causing hypertension by stimulating RVLM neurons directly via the production of oxidative stress in these neurons.
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